SAN DIEGO, March 23, 2016 /PRNewswire/ -- HUYA Bioscience International, the world’s leader in globalizing biopharma innovation, today announced the appointment of John Ratliff as President/CEO. This appointment is part of the company’s long term growth plan. Dr. Mireille Gillings, who founded the company, continues as Executive Chair of its Board of Directors.
John Ratliff brings over 30 years of experience in the biopharmaceutical and information technology industries. He led Quintiles’ Global Services organization as President/COO with its clinical research, commercial, consulting, lab operations. He helped lead the $1B 2013 IPO for the company in 2013.
“John has an impressive track record of operational and clinical development history. We are confident that he will lead the execution of our immune oncology franchise drug development strategy, which includes our recent in licensing of IDO programs,” said Dr. M. Gillings, Founder and Executive Chair. “We are delighted to welcome him on board.”
Mr. Ratliff also worked for Acterna, the world’s second largest provider of communications test solutions for telecommunications and cable network operators. Before moving to Acterna in 2000, he worked 19 years at IBM, holding several positions of increasing executive responsibilities. John received his bachelor’s degree in industrial and systems engineering from the Georgia Institute of Technology in Atlanta and his MBA from Duke University in Durham, North Carolina.
About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. In addition, to the lead compound HBI-8000, the Company also has two other pipeline drugs in development for arrhythmia and acute myocardial infarct. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. HUYA received the Asia-Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category and Dr. Mireille Gillings received the Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit www.huyabio.com.
Contact details:
Yiota Merianos
Director of Communications
+1-858-353-1217
ymerianos@huyabio.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/huya-bioscience-international-adds-to-executive-team-300240141.html
SOURCE HUYA Bioscience International
